Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EIF4A2
REST API REST API
Homo sapiens
EIF4A2 is differentially expressed in 271 experiments: 105 organism parts: bone marrow, liver, ... (103 more);, 169 disease states: normal, control, ... (167 more);, 69 cell types 297 cell lines 41 compound treatments and 68 other conditions.
Synonyms EIF4F, BM-010, EIF4A, DDX2B
Orthologs IF4A2_CHICK (Gallus gallus)   TIF1 (Saccharomyces cerevisiae)   F6TMJ9_CIOIN (Ciona intestinalis)   F6WTF3_CIOIN (Ciona intestinalis)   Eif4a2 (Rattus norvegicus)   eif4a2 (Danio rerio)   IF4A2_BOVIN (Bos taurus)   TIF2 (Saccharomyces cerevisiae)   D3ZVJ6_RAT (Rattus norvegicus)   Eif4a2 (Mus musculus)   eIF-4a (Drosophila melanogaster)   eif4a2 (Xenopus laevis)   EIF4A2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, nuclear-transcribed mRNA poly(A) tail shortening, eukaryotic translation initiation factor 4F complex, ATP-dependent helicase activity, nucleic acid binding, RNA metabolic process, cellular protein metabolic process, regulation of translational initiation, translation, ATP binding, translational initiation, translation initiation factor activity, nucleotide binding, nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay, hydrolase activity, RNA binding, helicase activity, mRNA metabolic process, gene expression, interspecies interaction between organisms
InterPro Term DNA/RNA_helicase_DEAD/DEAH_N, RNA_helicase_DEAD_Q_motif, Helicase_C, DEAD-like_helicase
UniProt Accession Q9NZE6, Q14240, C9JUF0, Q96B07, E7EMV8, E7EQG2, E9PBH4, F8WE11
Search EB-eye ENSG00000156976
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-22541, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
HepG2
2
E-GEOD-7307, E-GEOD-21154
MCF-7
2
E-GEOD-3529, E-GEOD-20081
MDA-MB-231
2
E-TABM-420, E-MTAB-62
BV-173
1
E-GEOD-7182
BHT101
1
E-MTAB-37
SNU5
1
E-MTAB-37
291 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13909, ... (38 experiments)

Factor Value U/D Experiments
cardiac myocyte
1
2
E-AFMX-5, E-MTAB-25, E-TABM-145
secretory cell
1
E-GEOD-3998
immortalised T lymphocytes
1
E-GEOD-13909
CD56+ NK cells
1
E-AFMX-5
liver cancer
1
E-GEOD-21154
bronchial epithelial
1
E-AFMX-5
63 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-GEOD-16363, E-GEOD-20168, E-MTAB-62, ... (56 experiments)

Factor Value U/D Experiments
Huntington's disease
3
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MEXP-567, E-GEOD-4412
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
obesity
2
E-MTAB-62, E-GEOD-2508
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
163 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (30 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5824, E-TABM-782, E-GEOD-412, E-GEOD-697, E-MEXP-1958, ... (12 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
4,5-dianilinophthalimide
1
1
E-GEOD-5258
Cxcl12
1
E-GEOD-7307
control - IL-1b
1
E-GEOD-7216
selenium
1
E-MEXP-1327
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-1751, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-MEXP-1235, E-GEOD-18736, E-TABM-43, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-6432, E-TABM-127, E-MEXP-1446, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-16363, E-GEOD-430, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561, E-GEOD-980, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-22309

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.435 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM